Rare Access Advisors

About Rare Access Advisors

Rare Access Advisors is an operator-led advisory firm focused on rare disease, specialty therapeutics, and cell & gene therapy. We help organizations build the patient, evidence, access, and commercialization infrastructure required to transform scientific innovation into patient impact. Today, extraordinary advances in science are reaching patients faster than ever before. Yet for many therapies, approval does not guarantee access, and access does not guarantee treatment. Increasingly, the success of a therapy depends on the strength of the ecosystem surrounding it—patient identification, advocacy engagement, evidence generation, reimbursement readiness, patient services, provider activation, site-of-care infrastructure, and operational execution. We believe the healthcare industry is facing a growing Infrastructure Gap™: the disconnect between scientific innovation and the operational capabilities required to successfully deliver treatment to patients. Rare Access Advisors was founded by senior healthcare operators who have spent decades building, leading, and optimizing commercialization, patient access, reimbursement, patient services, advocacy, and specialty distribution organizations across rare disease and specialty therapeutics. Unlike traditional consulting firms, we do not advise from the sidelines. We have been accountable for launch readiness, market access, patient services, treatment activation, provider engagement, and treatment durability in the real world. Our clients benefit from direct access to experienced operators who understand both strategy and execution. We intentionally remain selective in the engagements we accept so that every client works directly with the firm's founders. Our expertise spans: • Rare Disease Commercialization Strategy • Ecosystem Readiness™ • Patient Advocacy & Community Infrastructure • Patient Experience & Evidence Generation • Market Access & Reimbursement Strategy • Patient Services Design & Optimization